Clay Siegall Contributions to Cancer Treatment

Clay B. Siegall is the founder and Chief Executive Officer of a biotechnology company called Seattle Genetics. He is popular due to his input in the research of cancer treatments. After years of experience in the pharmaceutical industry, Siegall founded Seattle Genetics in 1998. Siegall has a Ph.D. in genetics from George Washington University. As a scientist, he has devoted most of his research time in technology that can be used in finding a cure for cancer. Besides acting as the CEO of Seattle Genetics, Clay Siegall sits on the board of trustees as the Chairman. Being a founding Father of the company, he built the company on the pillars of research, innovation, and drug development practices. These three elements combined with his constant desire to help cancer patients has seen the company rise to the top in the pharmaceutical industry. As a matter of fact, it is listed among the pioneers in the development of Antibody Drug Conjugates (ADCs).

Before founding this company, Siegall’s career began at National Institute of Health. He worked with this company for three years. He then joined Bristol-Myers Squibb Pharmaceutical and worked with them for seven years. He had also worked with the National Cancer Institute. Today, he sits on the board of trustees at Alders pharmaceutical. He is also on the board in Biopharmaceuticals. Biopharmaceuticals have played a primary role in the lives of people through its drugs.

As the CEO of Seattle Genetics, he has managed to accomplish several important things. First, the production of ADCs is a breakthrough in the fight against cancer. Antibody Drug Conjugates (ADCs) are drugs used to suppress any further growth of cancer cells. Despite rising the company a notch higher, a lot of patients have benefited from the use of this drug. Through the company’s innovative research team, the drugs have undergone series of improvements and have since been accepted in 66 nations.

Clay Siegall presence was felt during the fifth annual CHI Antibody Drug Conjugates Conference. He confirmed that drugs produced by his company had successfully contained Lymphoma in over 15,000 patients. According to Clay, the company intends to increase its workforce. As a result, projects and continuous advances will be maintained

The 2016 Q2 Results and Reactions of Seattle Genetics

October 13th, 2016 — UPDATE — Seattle Genetics makes good on their word to hire 100 more employees :


On July 26, 2016, Seeking Alpha reported about the 2016 Q2 results (earnings call transcript) of Seattle Genetics. The attendance list included Seattle Genetics executives such as Todd Simpson, Clay B. Siegall, and Peggy Pinkston who are the Chief Financial Officer, CEO, and the Executive Director of Corporate Communications respectively. Further, analysts from various representatives from financial institutions such as Leerink Partners LLC, Goldman Sach & Co., Needham & Co. LLC as well as Credit Suisse Securities were also present at the conference call.

Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript

The Chairperson and CEO of Seattle Genetics, Clay Siegall was pleased with the accomplishments of the company, especially in establishing ADCETRIS as a leading franchise. Further, Clay Siegall commended the company’s efforts in its continued efforts to become an international multi-product oncology company.

The aggregate revenue in the Q2 was stated as $95.4 million, which also included the record sales of ADCERIS, $66.2 million. This was a significant increment of 20% compared to last year’s second quarter results. Through Clay, the company expressed optimism in achieving its 2016 ADCETRIS net sales guidance in Canada and the U.S of $225 o $275 million.

In-depth information About Seattle Genetics and Clay Siegall

Seattle Genetics refers to a biotechnology company that is devoted towards establishing and commercializing empowered, innovative antibody-based therapies for curing or treating cancer. Consequently, it has created a cemented reputation as a leader in the development of antibody-drug conjugates or rather ADCs. ADCs are developed to harness the targeting capabilities of monoclonal antibodies to kill cancer cells by delivering cell-killing agents. They kill cancer cells while sparing non-targeted cells. This reduces the toxic effects, which are common for traditional chemotherapy.

Clay B. Siegall is the man at the helm of the operations at Seattle Genetics. He serves the company as the Chief Executive Officer as well as its chairperson. He is also credited for co-founding the company in 1998. Before founding Seattle Genetics, Clay had worked for numerous companies such as the National Institutes of Health, the Bristol-Myers Squibb Pharmaceutical Research Institute as well as the National Cancer Institute. He is an alumnus of the University of Maryland and George Washington University where he attained a Bachelor of Science degree in Zoology as well as a PH.D. in Genetics respectively.